Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CLYM vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)

CLYM Overall Winner 6-Pillar Tally: CLYM 2 – 2 LYRA (2 Tie) Matrix Metrics: CLYM 6 – 1 LYRA

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. CLYM 45.7/100 HOLD), CLYM captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY).
  • Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs LYRA
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap $608.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.52β · 112% Vol
Unified Composite Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 43
RSI-14: 43.4 · SMA20: $10.22 · SMA50: $11.34
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (CLYM 2 – 2 LYRA)

Columns: Metric · CLYM · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale CLYM
Revenue Growth (YoY) +0.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $608.5M $2.3M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.3% -404.5%
4. Balance Sheet & Cash Flow LYRA
Cash Generation (TTM) N/A -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (6) vs LYRA (1)
Institutional Metric CLYM LYRA Criterion Row Edge
Market Capitalization
Scale
$608.5M $2.3M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -87.2% Higher Growth CLYM
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.3% -404.5% Higher ROE CLYM
52-Week Range Position
Momentum
48% ($2–$18) 1% ($0–$38) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.52β · 112% Vol 0.33β · 248% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
45.7 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite LYRA
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLYM +97.79 pp
CLYM: +35.29% · LYRA: -62.5%
3M Horizon CLYM +297.62 pp
CLYM: +210.0% · LYRA: -87.62%
6M Horizon CLYM +362.4 pp
CLYM: +275.26% · LYRA: -87.14%
1Y Horizon CLYM +362.4 pp
CLYM: +275.26% · LYRA: -87.14%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs LYRA. Trailing 12-month operating profitability (CLYM 0.0% vs LYRA -25032.0%) and valuation multiples (CLYM N/M vs LYRA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
LYRA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$600,000
Gross MarginN/A
Op. Margin-25032.0%
ROE / Fwd P/E-404.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CLYM carries a Unified Composite Score of 45.7/100 (HOLD) at $9.64 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Composite vs. Pillar Nuance: While LYRA currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. CLYM 45.7/100 HOLD), CLYM captures the overall institutional head-to-head verdict (6–1 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -25032.0% operating margin) and revenue trajectory (+0.0% vs. -87.2% YoY). Technical & Structure Timing Caution: CLYM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.4); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CLYM leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $600,000 for LYRA. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 112% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.